We are live on ! Find out more
AA

ALPS Advisors Portfolio holdings

AUM $21.3B
1-Year Est. Return 21.71%
This Fund
S&P 500
This Quarter Est. Return
+5.24%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$15.2B
AUM Growth
-$88.9M
Cap. Flow
-$687M
Cap. Flow %
-4.5%
Top 10 Hldgs %
44.55%
Holding
1,138
New
213
Increased
453
Reduced
272
Closed
195

Sector Composition

Rank Sector Weight
1 Energy 55.03%
2 Financials 7.13%
3 Healthcare 4.31%
4 Consumer Discretionary 2.88%
5 Industrials 2.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AGI icon
151
Alamos Gold
AGI
$12.4B
$5.91M 0.04%
1,282,648
-11,132
-0.9% -$54.8K
MDGL icon
152
Madrigal Pharmaceuticals
MDGL
$12.6B
$5.82M 0.04%
27,194
+6,615
+32% +$1.66M
PAGP icon
153
Plains GP Holdings
PAGP
$5.23B
$5.82M 0.04%
237,286
+104,004
+78% +$2.58M
HZNP
154
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.77M 0.04%
294,872
+56,548
+24% +$1.08M
ARRY
155
DELISTED
Array Biopharma Inc
ARRY
$5.69M 0.04%
374,570
+70,370
+23% +$1.08M
PAAS icon
156
Pan American Silver
PAAS
$18.6B
$5.66M 0.04%
383,110
+139,495
+57% +$2.23M
BIP icon
157
Brookfield Infrastructure Partners
BIP
$18.8B
$5.59M 0.04%
235,366
-20,469
-8% -$487K
META icon
158
Meta Platforms (Facebook)
META
$1.51T
$5.43M 0.04%
32,990
+973
+3% +$176K
AKCA
159
DELISTED
Akcea Therapeutics Inc
AKCA
$5.31M 0.03%
151,688
+28,320
+23% +$857K
SUPN icon
160
Supernus Pharmaceuticals
SUPN
$2.68B
$5.17M 0.03%
102,660
+17,664
+21% +$872K
HALO icon
161
Halozyme
HALO
$9.72B
$5.15M 0.03%
283,377
+53,811
+23% +$943K
IAG icon
162
IAMGOLD
IAG
$8.47B
$5.1M 0.03%
1,384,802
-60,643
-4% -$288K
LTC
163
LTC Properties
LTC
$2.16B
$4.94M 0.03%
112,000
AERI
164
DELISTED
Aerie Pharmaceuticals
AERI
$4.93M 0.03%
80,025
+23,058
+40% +$1.48M
AUY
165
DELISTED
Yamana Gold, Inc.
AUY
$4.83M 0.03%
1,937,888
-215,282
-10% -$598K
BTG icon
166
B2Gold
BTG
$5.16B
$4.73M 0.03%
2,056,205
-160,918
-7% -$382K
XLRN
167
DELISTED
Acceleron Pharma
XLRN
$4.66M 0.03%
81,407
+14,975
+23% +$736K
ASND icon
168
Ascendis Pharma A/S
ASND
$16.7B
$4.64M 0.03%
65,448
+12,124
+23% +$835K
MYOK
169
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$4.63M 0.03%
70,988
+13,833
+24% +$813K
MSFT icon
170
Microsoft
MSFT
$2.84T
$4.59M 0.03%
40,149
-4,653
-10% -$504K
IRWD icon
171
Ironwood Pharmaceuticals
IRWD
$611M
$4.55M 0.03%
294,079
+56,596
+24% +$895K
AG icon
172
First Majestic Silver
AG
$8.05B
$4.48M 0.03%
788,185
-173,597
-18% -$1.08M
BAC icon
173
Bank of America
BAC
$435B
$4.44M 0.03%
150,709
+27,835
+23% +$848K
VB icon
174
Vanguard Small-Cap ETF
VB
$79.5B
$4.37M 0.03%
26,885
HRTX icon
175
Heron Therapeutics
HRTX
$86.3M
$4.35M 0.03%
137,559
+33,836
+33% +$1.26M

Similar funds

ALPS Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, ALPS Advisors held 1,138 positions worth $15.2B, down 0.58% from $15.3B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

ALPS Advisors withdrew a net $687M in Q3 2018, closing 195 positions and reducing 272 holdings. Its most notable exit was Williams Partners L.P., an estimated $859M position sold in full.

By sector, the portfolio is most concentrated in Energy at 55% of assets, up from 54% a quarter earlier, followed by Financials and Healthcare.

Against the trend, ALPS Advisors opened a new position in Kirkland Lake Gold Ltd Ordinary worth $19.6M.

  • ALPS Advisors's largest Q3 2018 buy was Kirkland Lake Gold Ltd Ordinary: 1,029,518 shares worth $19.6M.
  • ALPS Advisors added most to Tallgrass Energy, LP Class A Shares in Q3 2018, an estimated $205M increase.
  • ALPS Advisors's biggest Q3 2018 reduction was Energy Transfer Partners, L.P., cutting an estimated $195M.
  • ALPS Advisors fully exited Williams Partners L.P. in Q3 2018, selling an estimated $859M.
  • ALPS Advisors's ten largest holdings make up 45% of its $15.2B portfolio in Q3 2018.
  • ALPS Advisors opened 213 new positions and closed 195 in Q3 2018.
  • ALPS Advisors's portfolio value fell 0.58% quarter-over-quarter to $15.2B.

Based on ALPS Advisors's 13F filing for Q3 2018, filed 25 Oct 2018.